Chlordiazepoxide half-life
The displayed 24-to-48-hour range refers to parent chlordiazepoxide in labeling context.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. The shaded band shows the reported half-life range. This is a mathematical visualization, not a personal concentration estimate.
Chlordiazepoxide: evidence and interpretation notes
The number behind the long tail
The displayed 24-to-48-hour range refers to parent chlordiazepoxide in labeling context. Active metabolites and repeated exposure can extend the practical pharmacokinetic story beyond that parent range.
The plotted input is 36 hours for Parent chlordiazepoxide. It is a normalized comparison line, not a reconstruction of a measured blood concentration or a forecast of effects.
Chlordiazepoxide may involve residual sedation, active metabolites, age-related differences, and co-medication effects. The curve is a parent-drug simplification, not a next-day impairment or withdrawal model.
What each source contributes
- DailyMed: CHLORDIAZEPOXIDE HYDROCHLORIDE CAPSULE [COUPER LLC]. This product label adds formulation-specific pharmacokinetic context and does not represent every route or product.
- PubChem: Chlordiazepoxide. This identity record confirms names and compound identity and does not supply a human half-life.
- Greenblatt DJ et al. Clinical pharmacokinetics of chlordiazepoxide (1978). This focused human review reports a shorter 5-to-30-hour single-dose range and explains why active metabolites and repeated exposure make the parent value population- and context-dependent.
For Chlordiazepoxide, the numerical model is tied most closely to DailyMed: CHLORDIAZEPOXIDE HYDROCHLORIDE CAPSULE [COUPER LLC]. As a product label, it adds formulation-specific pharmacokinetic context; it does not represent every route or product.
Why the range stays visible
The 24-to-48-hour range is retained beside the 36-hour input for Parent chlordiazepoxide. It is not an uncertainty slider or a personalized prediction; it shows that the cited literature does not reduce to one invariant value.
InterpretationReading the curve and its category context
Reading this curve
HalfLifeDB uses 36 h as a representative input for Parent chlordiazepoxide. In the simplified model, about 63.0% remains after 24 hours and about 3% remains after five half-lives, or roughly 7.5 days.
This is a long-tail curve. The page is most useful for understanding persistence and accumulation concepts, not for making decisions from one percentage. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
benzodiazepine context
Benzodiazepine half-life estimates can be especially sensitive to active metabolites, redistribution, age, liver function, and repeated use.
- A long terminal half-life does not mean effects remain constant for the whole period.
- Shorter-acting entries can still have residual effects after the main subjective effects fade.
- Repeated exposure can create overlap that a single-dose curve does not show.
ComparisonTimeline checkpoints and nearby profiles
Chlordiazepoxide timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 24 h | 63.0% | Meaningful modeled decline, not near-zero |
| 3.0 days | 25.0% | Long-tail portion of the model |
| 5.0 days | 9.92% | Low modeled remainder, not a clearance guarantee |
| 7.0 days | 3.94% | Low modeled remainder, not a clearance guarantee |
| 14 days | 0.16% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Chlordiazepoxide within the benzodiazepine group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
- Clonazepam (34 h)
- Diazepam (30 h)
- Lorazepam (14 h)
- Alprazolam (11.2 h)
EvidencePharmacokinetic inputs and source trail
Pharmacokinetics at a glance
| Representative half-life | 36 h |
|---|---|
| Modeled analyte or phase | Parent chlordiazepoxide |
| Reported range | 24 h to 2.0 days |
| Curve type | Normalized, first-order decline |
Selection note: The displayed 24-to-48-hour range refers to parent chlordiazepoxide in labeling context. Active metabolites and repeated exposure can extend the practical pharmacokinetic story beyond that parent range.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Official labeling DailyMed label: CHLORDIAZEPOXIDE HYDROCHLORIDE CAPSULE [COUPER LLC].Official U.S. product labeling used for formulation and labeled pharmacokinetic context; its statements apply to the described product.
- Identity record PubChem Compound Summary: Chlordiazepoxide.Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
- Research abstract Greenblatt DJ et al. Clinical pharmacokinetics of chlordiazepoxide (1978).Focused human pharmacokinetic review reporting a 5-to-30-hour single-dose parent range and describing the succession of active metabolites. The profile keeps the current label's 24-to-48-hour statement as the plotted range rather than merging unlike estimates.
BoundariesWhat this page cannot answer and where to continue
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the benzodiazepine group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and research standards before using the model for comparison.